Insider Selling: Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells 22,355 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 22,355 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.65, for a total transaction of $171,015.75. Following the completion of the transaction, the general counsel now owns 175,496 shares in the company, valued at $1,342,544.40. The trade was a 11.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Pulmonx Trading Down 9.2 %

Shares of Pulmonx stock opened at $7.44 on Friday. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $10.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The company has a market capitalization of $296.08 million, a P/E ratio of -5.17 and a beta of 0.50. The company has a fifty day moving average of $6.95 and a 200 day moving average of $6.94.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, sell-side analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LUNG. Wells Fargo & Company decreased their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Citigroup reaffirmed a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.75.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently added to or reduced their stakes in LUNG. FMR LLC boosted its position in shares of Pulmonx by 11.2% during the third quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after acquiring an additional 591,859 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Pulmonx in the 4th quarter worth $10,421,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Pulmonx by 5.2% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after purchasing an additional 55,279 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Pulmonx by 2.4% during the third quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock valued at $8,750,000 after purchasing an additional 25,002 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Pulmonx by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 902,240 shares of the company’s stock worth $6,128,000 after purchasing an additional 9,454 shares during the last quarter. 91.04% of the stock is owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.